ESG News For Teva Pharmaceuticals

Reaching 100% renewable electricity in 10 years - that’s a bold target. And bold targets require bold solutions. One way we’re working toward this target is through Virtual Power Purchase Agreements, or VPPAs.

Teva is proud to be included in the 2025 TIME and Statista list of the World’s Most Sustainable Companies, a recognition that underscores our commitment to building a healthier, more sustainable world.

Improving access to medicines and healthcare requires a continued effort to develop new evidence-based solutions that address unmet needs.

Teva Pharmaceuticals has been recognized with the 2025 Power of Partnership Award by Americares, in collaboration with the Healthcare Distribution Alliance (HDA), for its exceptional commitment to expanding access to medicines for underserved communities around the world.

In order to achieve lasting impact, we have expanded a number of our access programs to go beyond the product by incorporating Health System Strengthening and Capacity Building efforts.

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved populations worldwide via customized, localized models conducted with partner organizations, and tailored to meet specific national health challenges.

At Teva, we are all in for better health. Increasing access to quality medicines is fundamental to improving the health of patients and the success of our business.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its 2024 Healthy Future Report, sharing actions to advance its sustainability strategy.

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income countries, this number tragically drops to 20%.

Breast cancer remains a significant health challenge globally with approximately 2.3M new cases in 2022. While breast cancer deaths continue to fall in many countries worldwide, in others the situation is very different.

Clinical trials are essential for the development of health care products, and it is increasingly recognized that there is a need for more diversity in trial participation.

We are pleased to announce the launch of a new program that donates vital medicines to underserved communities in El Salvador.

Last year, we took bold steps to ensure our sites were addressing antimicrobial resistance (AMR) throughout the entire manufacturing process.

Teva Pharmaceuticals is proud to share that our Community Routes: Access to Mental Health Care U.S. access program, in partnership with Direct Relief and NAFC, has been recognized by the U.S. Chamber of Commerce Foundation 25th annual Citizens Award.

Diversity and inclusion are not only core elements of Teva’s cultural DNA, they are also key in realizing our Pivot to Growth strategy.

For years sustainability has been all about transparency. Reporting is the cornerstone of disclosing why, what and how companies advance their long-term goals. But consistency remains a challenge for Environmental, Social and Governance (ESG) reporting.

Teva was recently named one of the most sustainable companies in the world by TIME magazine and data firm Statista. The inaugural list measured how some of the biggest and most influential companies are living up to their promises to protect our planet.

Teva’s 2023 Healthy Future Report highlights the Company’s renewed sustainability strategy, which guides Teva in addressing global challenges while also supporting its business, allowing for the continued supply of medicines for patientsNew ambitious targets are centered on net zero emissions, renewable electricity and a holistic approach to health system strengthening and capacity building to support underserved populationsA second series of sustainability-linked bonds (SLBs), valued at $2.49 billion, brought Teva’s SLB total to $7.5 billion—making Teva the largest issuer in the pharmaceutical sector and the second largest across all sectors worldwide

Recap of CSR stories on Business Wire

Launched five access to medicines programs as of 2022 (63% of 2025 target); donated $699.6 million worth of medicines to patients in needReduced absolute scope 1 and 2 greenhouse gas (GHG) emissions by 24% (vs. 2019) and absolute scope 3 GHG emissions by 12% (vs. 2020); met or exceeded 2030 targets to increase energy efficiency and reduce total water withdrawal in areas projected to be in water stressRanked in the top 10% of the industry in key ESG rating indices, including S&P Global, ISS ESG and EcoVadis

“Community Routes: Access to Mental Health Care” helps uninsured patients access healthcare for anxiety and depression, and is a partnership between Direct Relief, the National Association of Free and Charitable Clinics (NAFC) and Teva PharmaceuticalsThe expansion of medicine donations for anxiety and depression into​ seven new states across the United States has the potential to extend the program’s reach to more than 650,000 uninsured patients through 400+ eligible clinicsThe program provides access to a portfolio of donated medicines for anxiety and depression, valued at over $17 million; Teva has committed $2 million of grant funding over two years to free and charitable clinics that care for uninsured patients

Recap of CSR stories on Business Wire

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint.As one of the world's largest manufacturers of generic medicines, Teva makes treatments more affordable and accessible - reaching nearly 200 million patients every day. With its vast global pr

National survey conducted by the Morehouse School of Medicine and Teva Pharmaceuticals shows intensified impacts among vulnerable populations driven by lack of access to care About 50% of healthcare consumers say they postponed or canceled healthcare services since the pandemic began64% of Black, Indigenous and people of color (BIPOC) delayed and/or canceled healthcare services during the pandemic84% of physicians report an increase in new diagnoses of mental health conditions since the pandemic began58% of healthcare consumers say they are likely to use telehealth to see/visit their doctor or healthcare provider after the pandemic

Recap of CSR stories on Business Wire

$5 billion bond is the largest of its kind from any sector and the first issued by a generic medicines companyThe bond is tied to targets that include improving access to medicines in low- and middle-income countries (LMICs) and reducing greenhouse gas (GHG) emissions

Virtual event, co-sponsored by Voya Financial and Disability:IN, will include appearances from notable Fortune 1,000 CEOs

Recap of CSR stories on Business Wire

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the company’s efforts to advance health and equity, minimize its impact on the planet and dedicate itself to quality, ethics and transparency.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005037/en/The report highlights new ambitious goals, including launching eight programs to

Hepatitis C: Another “Child” of the Drug Industry, Says Ohio’s Yes on Issue 2 Campaign